CRI Assistant Director of Scientific Affairs Samik Upadhaya, PhD, will present a talk, “Racial and Ethnic Diversity in Immuno-Oncology Clinical Trials” as part of the session, “Reaching More Patients with CGT: Screening, Genomics, Databases, and Patient Diversity” on January 19, 2023. He will review the current landscape of patient diversity in immuno-oncology trials leading to FDA approval and discuss challenges and opportunities to increase patient diversity in oncology trials.
CRI Anna-Maria Kellen Clinical Accelerator and Venture Fund Research Analyst Ana Rosa Sáez Ibáñez, PhD, will chair the session, “Disruptive and Novel Therapeutics for Oncology Indications” featuring four presentations from Troels Jordansen, CEO, Glycostem Therapeutics; Anne Cox, Director of Business Development, Tensentric; Jeff Liter, CEO, Luminary Therapeutics; and Allen Feng, CSO, HebeCell, followed by a panel discussion and Q&A, on January 20, 2023.
